Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in Secondary Prevention of Cardiovascular Disease (China)
CTR20150063Phase 3Active
- Sponsor
- Amgen
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab in cardiac morbidity, coronary arteriosclerosis, cerebrovascular disease, arteriosclerosis obliterans, atherosclerotic disease, sponsored by Amgen. Started Feb 2015; status: active.
02
Drugs
evolocumab
03
Conditions
cardiac morbiditycoronary arteriosclerosiscerebrovascular diseasearteriosclerosis obliteransatherosclerotic disease
Beyond the preview
Go deeper on CTR20150063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150063.